(SXTP) 60 Degrees Pharmaceuticals, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SXTP) 60 Degrees Pharmaceuticals, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This 60 Degrees Pharmaceuticals, Inc. 4P's Marketing Mix Analysis shows the company’s Product, Price, Place and Promotion strategy and explains what the offering is and how it’s used; the page already includes a real preview/sample of the analysis so you can review style and content before buying — purchase the full version to get the complete ready-to-use report.
Product
1 approved product: Arakoda
Arakoda is 60 Degrees Pharmaceuticals’ only approved commercial product and the company’s marketed asset. It is a tafenoquine-based malaria prophylaxis for adults, giving the firm a revenue platform while it advances its pipeline. As the only approved product, Arakoda anchors the Product mix with a clear, FDA-cleared treatment offering in a niche malaria-prevention market.
Phase IIb tafenoquine for COVID-19
60 Degrees Pharmaceuticals, Inc. is studying tafenoquine in Phase IIb for COVID-19 using the Arakoda regimen, extending one active ingredient beyond malaria prevention. Arakoda is already the Company Name’s FDA-approved malaria prophylaxis product, so this trial tests whether the same asset can support a broader infectious-disease platform. If successful, it could improve asset reuse and raise the commercial value of tafenoquine.
Phase IIA tafenoquine for 3 indications
Phase IIA tafenoquine spans babesiosis, fungal pneumonias, and candidiasis, keeping 60 Degrees Pharmaceuticals, Inc. squarely in infectious disease. The three programs widen the drug’s addressable market beyond malaria and support pipeline depth if results hold. For a small-cap biotech, that kind of multi-indication reuse can lower development risk and raise future revenue upside.
Celgosivir for 3 viral diseases
Celgosivir gives 60 Degrees Pharmaceuticals, Inc. a second investigational asset beyond tafenoquine, and it is being developed for 3 viral disease areas: Zika, respiratory viruses, and dengue fever. That broader pipeline can reduce single-asset risk and widen future use cases. One asset, 3 shots at value.
- 3 target viral disease areas
- Second investigational asset
- Broadens portfolio beyond tafenoquine
Tufts Medical Center license for babesiosis
60 Degrees Pharmaceuticals, Inc. holds a patent license agreement with Tufts Medical Center for tafenoquine in babesiosis, a niche tick-borne disease market. The deal supports product development rights for both treatment and prevention, which can widen the Company Name's pipeline value without needing a full new-drug discovery program.
- Tufts Medical Center backs tafenoquine rights
- Targets babesiosis treatment and prevention
- Strengthens niche infectious-disease positioning
One Approved Drug, Multiple Pipeline Shots for 60 Degrees Pharmaceuticals
Arakoda is 60 Degrees Pharmaceuticals, Inc.'s only approved product and the core of its Product mix, giving the Company Name one FDA-cleared malaria prophylaxis asset. Beyond malaria, tafenoquine is also being tested in Phase IIb COVID-19 and Phase IIA babesiosis, fungal pneumonia, and candidiasis, so one molecule supports multiple shots at value. Celgosivir adds a second investigational asset across Zika, respiratory viruses, and dengue fever.
| Product | Status | Use |
|---|---|---|
| Arakoda | Approved | Malaria prophylaxis |
| Tafenoquine pipeline | Phase IIb / IIA | COVID-19, babesiosis, fungal pneumonia, candidiasis |
| Celgosivir | Investigational | Zika, respiratory viruses, dengue |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of 60 Degrees Pharmaceuticals, Inc. showing how Product, Price, Place, and Promotion shape its market strategy.
Editable Excel File
Condenses 60 Degrees Pharmaceuticals’ 4Ps into a quick, clear view that simplifies decision-making and marketing alignment.
Reference Sources
Provides a concise, traceable bibliography of industry reports, government data, and benchmarks to quickly verify 60 Degrees Pharmaceuticals’ market, pricing, and competitive claims.
Place
Washington, D.C. headquarters
60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., placing key decisions in the U.S. capital. That location gives the Company direct access to federal regulators, policy makers, and investors. Washington, D.C. has about 700,000 residents and a dense institutional network, which supports visibility and access.
U.S. infectious-disease focus
60 Degrees Pharmaceuticals, Inc. keeps its place strategy centered on the U.S. infectious-disease market, not a wide consumer retail network. The company’s U.S.-first footprint fits its FDA-regulated products and small scale, with 2025 filings showing a market value near $20 million and a very limited commercial base. That makes the United States the core geography in its marketing mix.
Prescription-access model
Arakoda is a prescription-only antimalarial, so access runs through U.S. healthcare providers and pharmacies, not OTC shelves. The FDA approved Arakoda in 2018, and its weekly dosing plus prescription status keep the product tied to clinical prescribing and pharmacy dispensing. That makes the place strategy a regulated distribution model, not direct retail.
Clinical-development sites
60 Degrees Pharmaceuticals, Inc. depends on clinical-development sites for its Phase IIb and Phase IIA trials, where investigational products are dosed and measured against protocol endpoints. These sites are a core part of the Company Name's development path because they determine enrollment speed, data quality, and trial cost. The company has not publicly broken out a site count in recent filings.
- Phase IIb and Phase IIA sites drive execution.
- They administer and assess investigational products.
- No public site-count disclosure was found.
Academic partnership channel
The Tufts Medical Center license gives 60 Degrees Pharmaceuticals, Inc. one U.S. academic medical institution channel for research and disease-specific expertise. That place-based link can speed access to clinical know-how, support development work beyond internal teams, and widen the company’s reach without building a full in-house academic network.
- 1 academic medical partner
- U.S.-based collaboration channel
- Expands research access
- Supports disease-specific expertise
60 Degrees’ U.S.-First Strategy Keeps Growth Narrow
60 Degrees Pharmaceuticals, Inc. uses a U.S.-first place strategy: Washington, D.C. for corporate access, U.S. pharmacies and prescribers for Arakoda, and trial sites for Phase IIb and Phase IIA work. With a 2025 market value near $20 million and no public site count, its reach stays narrow and regulated.
| Place factor | Data |
|---|---|
| HQ | Washington, D.C. |
| Product access | Prescription-only U.S. pharmacies |
| Trials | Phase IIb, Phase IIA sites |
| 2025 market value | Near $20 million |
Full Version Awaits
60 Degrees Pharmaceuticals, Inc. Reference Sources
The preview shown here is the actual 4P's Marketing Mix analysis for 60 Degrees Pharmaceuticals, Inc. you’ll receive instantly after purchase—fully complete, editable, and ready to use with product, price, place, and promotion insights tailored to the company.
Promotion
FDA-approved product message
Arakoda, approved by the FDA in December 2018, is 60 Degrees Pharmaceuticals, Inc.'s main promotional proof point. One regulated product in market makes the brand easier to trust, because it shows the company can meet FDA standards and support commercialization. That credibility can help lower resistance when the firm promotes its pipeline and future label expansion plans.
Clinical-trial milestone updates
Clinical-trial milestone updates are a core promotion tool for 60 Degrees Pharmaceuticals, Inc., with Phase IIb and Phase IIA progress signaling real pipeline traction to investors, partners, and clinicians. The company uses these readouts to keep the story moving while commercial sales stay limited, and mid-stage data often matter more than near-term revenue. Each milestone can support value, since one positive trial update can shift attention faster than a small sales base.
Infectious-disease specialization
60 Degrees Pharmaceuticals, Inc. keeps its promotion tight around infectious diseases, so the brand reads as a specialist, not a broad pharma player. Its lead product, ARAKODA, is a tafenoquine malaria drug approved by the U.S. FDA, which gives the message a clear high-need focus. That niche positioning helps the company stand out in a small but clinically urgent market.
Tufts collaboration announcement
60 Degrees Pharmaceuticals, Inc.'s patent license agreement with Tufts Medical Center is a strong promotion point because it shows outside scientific backing and adds credibility to the pipeline. For investors and stakeholders, a named research partner can reduce perceived development risk and support confidence in the Company’s R&D story.
- Tufts deal signals validation
- Boosts scientific credibility
- Supports investor confidence
Public-company disclosures
60 Degrees Pharmaceuticals, Inc. uses SEC filings, press releases, and investor materials to share product, pipeline, and corporate updates. For a U.S. listed company, these channels matter most when a promotion is tied to clinical milestones, since the filing trail and public releases give investors a clear record of progress and risk.
- SEC filings support formal disclosure.
- Press releases speed milestone updates.
- Investor decks explain pipeline plans.
- Clinical data can drive promotion.
Arakoda Approval and Clinical Updates Drive 60 Degrees Promotion
Promotion at 60 Degrees Pharmaceuticals, Inc. is built on Arakoda’s FDA approval, malaria focus, and clinical updates that keep the pipeline visible. SEC filings, press releases, and investor materials are the main channels, while the Tufts Medical Center license adds scientific credibility.
| Signal | Promotion value |
|---|---|
| Arakoda FDA-approved | Trust anchor |
| Phase IIb/IIA updates | Pipeline visibility |
| Tufts license | Scientific validation |
Price
Arakoda price not disclosed
Arakoda price is not disclosed in the supplied Company Name data, so exact pricing cannot be verified here.
That means Company Name’s commercial price point for Arakoda is not stated in this material, and no public list price is provided.
Without a disclosed 2025/2026 price, the pricing element of the 4P mix stays unconfirmed.
1 marketed product, 4 pipeline programs
60 Degrees Pharmaceuticals, Inc. has 1 marketed product and 4 pipeline programs, so price today is tied to the approved product only. The company’s investigational candidates have no commercial pricing yet, since they are still in development. For pricing, the focus is on access, reimbursement, and net realized sales for the marketed product, not the pipeline.
Prescription-market pricing
Arakoda is an FDA-approved prescription drug, so its price is set inside the U.S. reimbursement system, where payers, pharmacies, and patient cost-sharing shape access. In 2025, Medicare Part D capped annual out-of-pocket drug costs at $2,000, which can matter for insured patients, but 60 Degrees Pharmaceuticals, Inc. did not disclose specific reimbursement terms.
No public discount terms
60 Degrees Pharmaceuticals, Inc. does not disclose public discount terms, so rebates, financing, and credit options are not visible in the company summary. That leaves the price structure unclear for buyers and investors, with no stated price breaks or trade incentives. In its latest public materials, the company still provides no quantified discount policy.
- No disclosed rebates or markdowns
- No financing or credit terms published
- Pricing remains unspecified
Specialty anti-infective economics
60 Degrees Pharmaceuticals, Inc. sells into specialty anti-infective markets, where demand is narrow and tied to clinical need, not mass retail volume. That makes price less about unit traffic and more about access, payer support, and proof of value, especially for products like ARAKODA used in malaria prevention.
In niche infectious-disease care, a higher list price can work only if it supports reimbursement and fits hospital, travel-medicine, or government buying channels. The company’s economics are shaped by small patient pools, high development cost, and the need to defend value with outcomes, safety, and convenience data.
- Small patient base
- Access drives pricing power
- Value proof matters most
- Payer and channel mix set realization
ARAKODA Price Unlisted, But Medicare Cap Shapes 2025 Costs
60 Degrees Pharmaceuticals, Inc. does not disclose a public 2025/2026 list price for ARAKODA, so the price point cannot be verified from supplied data. Pricing is therefore driven by payer access, pharmacy channels, and patient cost-sharing, not a stated sticker price. Medicare Part D’s $2,000 annual out-of-pocket cap in 2025 can affect insured buyers. No rebates, discounts, or credit terms were disclosed.
| Price factor | 2025/2026 data |
|---|---|
| ARAKODA list price | Not disclosed |
| Medicare Part D OOP cap | $2,000 |
| Discount terms | Not disclosed |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.